Readers Note:
This 'paper' starts from a highly questionable place.
"On the last day of parliament before the general election in 2024, the government imposed a ban on puberty-blockers, criminalizing their use for young trans people. The incoming Labour government of Keir Starmer continued this ban and subsequently made it permanent, enforcing it with a criminal sanction of up to two years in prison. This has made the UK an international outlier, countries as diverse as Spain, France, Norway, Denmark, Poland, Germany, Japan, South Africa, The Netherlands, Switzerland, Belgium, Mexico, Canada, Australia, New Zealand and many others routinely prescribe puberty blockers for young people with gender incongruence. Puberty-blockers have been used to treat young trans people since the 1990s, meaning that there are now trans people in early middle age who were prescribed them. Puberty-blockers provide young trans people with the time to think and make a decision about their future when they are more mature and regarded as legally competent to do so. Their effects are fully reversible. Puberty-blockers suspend puberty, and that is all they do. They are also prescribed in the UK for precocious (ie early) puberty and for people with prostate cancer and endometriosis."
For a start, France, Norway, Denmark, Canada, New Zealand and I believe, even Germany, have all had independent teams that have stated that there is low evidence that puberty blockers and other treatments lead to a improved outcome for children and young people.
"Puberty-blockers provide young trans people with the time to think and make a decision about their future when they are more mature and regarded as legally competent to do so. Their effects are fully reversible."
This is just propaganda in view of all that is now known about these drugs. It is very dangerous misinformation.
For a start for female people, bone density issues are significant for any female person who takes puberty blockers and then moves on to taking testosterone. This is in keeping too with the adult outcomes of girls being prescribed PBs for precocious puberty. Decades later, those women report bone density issues and joint and connective tissue issues. Teeth falling out, osteoporosis, jaws dislocating and a huge range of damage to organs.
This is known. Yet it is dismissed by male people who seem to have far too heavy investment in spreading the propaganda.
Here is one study that shows that "Their effects are fully reversible" is dangerous misinformation.
Bone Health in the Transgender Population
Published online 2019 Jul 2.
Micol S. Rothman and Sean J. Iwamoto
www.ncbi.nlm.nih.gov/pmc/articles/PMC6709704/
Also unknown are the long-term effects of puberty blockade, the effect of changes in body composition and the optimal type, timing, dosage, and route of administration of GAHT for bone outcomes.
Conclusion
The results of the studies that reported impact on the critical outcomes of gender dysphoria and mental health (depression, anger and anxiety), and the important outcomes of body image and psychosocial impact (global and psychosocial functioning), in children and adolescents with gender dysphoria are of very low certainty using modified GRADE. They suggest little change with GnRH analogues from baseline to follow-up.
And
GnRH analogues are frequently employed to provide puberty blockade in adolescents with gender incongruence or gender dysphoria. From their use in other medical conditions such as prostate cancer, their deleterious effects on the bone are well known, although these have the potential to be reversible if treatments are stopped or add back therapies can be given
And
However, Z-scores in the trans boys also showed an expected drop during GnRHa treatment. Similarly, they did not fully make up their bone loss as Z-scores at age 22 were still lower than baseline
Meaning, the authors acknowledge little is known about the lasting effects of puberty blockers. In this study, they propose some positive effect from cross sex hormones for females but ths results show that it doesn’t really make up the loss from puberty blockers.
PLUS
Just adding this piece about bone density for young transitioners here:
https://segm.org/the_effect_of_puberty_blockers_on_the_accrual_of_bone_mass
1st May 2021
Dr Michael Biggs (an advisor to SEGM) has been calling for the release of data from the Tavistock’s experiment since 2019. A subset of the data were finally released following the judicial review into puberty suppression at the Tavistock clinic. Biggs’ reanalysis has just been published in the Journal of Paediatric Endocrinology and Metabolism. It finds that after two years on GnRHa, the Z-scores for a significant minority of the children had declined to a level that should trigger clinical concern.
PLUS
www.svtplay.se/video/33358590/uppdrag-granskning/mission-investigate-trans-children-avsnitt-1
The latest from Sweden on the effects of puberty blockers on Leo and others.
As the poster who posted this initially states:
A trans child, Leo was treated for puberty blockers for 4 years. Leo ended up with osteoporosis (significantly below any normal bone density interval), fractures in the back, constant pain and worse mental state.
The journalist also found an additional 12 cases in Stockholm only where children had serious side effects (bone fractures, deep regret from voice changes, injuries, deteriorating mental health and significant weight gains). Leo’s case was not reported and not one of these.
That doesn't even cover this warning:
New FDA warning for PBs:
publications.aap.org/aapnews/news/20636/Risk-of-pseudotumor-cerebri-added-to-labeling-for?autologincheck=redirected
The Food and Drug Administration (FDA) has added a warning about the risk of pseudotumor cerebri (idiopathic intracranial hypertension) to the labeling for gonadotropin-releasing hormone (GnRH) agonists that are approved for the treatment of central precocious puberty in pediatric patients. These products include Lupron Depot-Ped (leuprolide acetate), Fensolvi (leuprolide acetate), Synarel (nafarelin), Supprelin LA (histrelin) and Triptodur (triptorelin).
The new warning includes recommendations to monitor patients taking GnRH agonists for signs and symptoms of pseudotumor cerebri, including headache, papilledema, blurred or loss of vision, diplopia, pain behind the eye or pain with eye movement, tinnitus, dizziness and nausea.
And
Six cases were identified that supported a plausible association between GnRH agonist use and pseudotumor cerebri. All six cases were reported in birth-assigned females ages 5 to 12 years. Five were undergoing treatment for central precocious puberty and one for transgender care. The onset of pseudotumor cerebri symptoms ranged from three to 240 days after GnRH agonist initiation.
Just a reminder : SEGM has a page with links to studies. This is a great archive.
It covers treatment, and side effects, mental health, suicide, even social transitioning.
https://segm.org/studies